Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Prelude Therapeutics Inc changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of PRLD: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders5560+5
Shares38.5M36.6M−1.93M (−5.0%)
Value$176.2M$113.1M−$63.1M (−35.8%)

New holders (7)

Institutions that held Prelude Therapeutics Inc at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to PRLD in Q3 2023
InstitutionSharesValue% of portfolio
Sio Capital Management, LLC350,000$1.08M0.33%
Pale Fire Capital SE30,781$95.1K0.01%
HSBC Holdings PLC23,198$70.8K0.00%
Acadian Asset Management LLC7,023$21.0K0.00%
Allspring Global Investments Holdings, LLC6,107$18.9K0.00%
Deutsche Bank AG446$1.38K0.00%
Simplex Trading, LLC31$00.00%

Sold out (2)

Institutions that held Prelude Therapeutics Inc at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of PRLD in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
UBS Asset Management Americas Inc2,273,894$13.0M
Mirae Asset Global Investments Co., Ltd.10,087$45.4K